Ouabain-like factor: Is this the natriuretic hormone?

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 2, 2000, Pages 165-171

  Ferrandi, Mara ^a   Manunta, Paolo ^b  

^a Prassis Sigma Tau Research Institute   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DIGITALIS LIKE FACTOR; NATRIURETIC FACTOR;

HEART LEFT VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SODIUM TRANSPORT;

BIOLOGICAL FACTORS; CARDENOLIDES; DIGOXIN; HUMANS; HYPERTENSION, RENAL; HYPERTROPHY, LEFT VENTRICULAR; NA(+)-K(+)-EXCHANGING ATPASE; NATRIURETIC AGENTS; RISK FACTORS; SAPONINS;

EID: 0034016155     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200003000-00011     Document Type: Review

References (70)

1. 1 de Wardener HE, Mlllis IH, Clapham WF, Hayter CJ. Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in dog. Clin Sci Mol Med 1961, 21:249-258.
2. 2 de Wardener HE, MacGregor G. Dahl's hypothesis that a saluretic substance may be responsible for a sustained rise in arterial pressure: its possible role in essential hypertension. Kidney Int 1980; 18:1-9.
3. 3 Haddy FJ, Overbeck HW. The role of humoral agents in volume expanded hypertension. Life Sci 1976; 19:935-948.
4. 4 Blaustein MP. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am J Physiol 1977; 232:C165-C173.
5. 5 Sagnella GA, Nolan DA, Shore AC, MacGregor G. Effects of atrial natriuretic peptide on sodium potassium transport in human erythrocytes. Clin Sci 1985, 69:223-226.
6. 6 Goto A, Yamada K. Ouabain-like factor. Curr Opin Nephrol Hypertens 1998; 7:189-196.
7. 7 Lewis LK, Yandle TG, Lewis JG, Richards AM, Pidgeon GB, Kaaja RJ, Nicholls MG. Ouabain is not detectable in human plasma. Hypertension 1994; 24:549-555.
8. 8 Ferrandi M, Manunta P, Balzan S, Hamlyn J, Bianchi G, Ferrari P. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 1997; 30:886-896.
9. 9 Hamlyn J, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, et al. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991; 88:6259-6263.
10. 10 Kawamura A, Guo J, Itagaki Y, Bell C, Wang Y, Haupert G, et al. On the structure of endogenous ouabain. Proc Natl Acad Sci USA 1999; 96:6654-6659.
11. 11 Zhao N, Lo LC, Berova N, Nakanishi K, Tymiak A, Ludens JH, Haupert GT. Na-K ATPase inhibitors from bovine hypothalamus and human plasma are different from ouabain: nanogram scale CD structural analysis. Biochemistry 1995; 34:9893-9896.
12. 12 Dong JC, Guo J, Akritopoulou-Zanze I, Kawamura A, Nakanishi K, Berova N. Theoretical and experimental CD of conformationally flexible complex molecules: application to ouabain pentanaphthoate and analogs. Chirality 1999; 11:707-721.
13. 13 Samuelov S, Lichtstein D. Digitalis-like compounds and Na-K ATPase activity in bovine lens. Eur J Physiol 1997; 433:435-441.
14. 14 McGowan M, Russell P, Carper D, Lichtstein D. Na-K ATPase inhibitors down-regulate gene expression of the intracellular signaling protein 14.3.3 in rat lens. J Pharmacol Exp Ther 1999; 289:1559-1563. This paper provides evidence of the molecular mechanisms activated by a bufadienolide derivative that, through the modulation of gene expression, can lead to pathological diseases such as cataract formation.
15. 15 Fedorova OV, Doris PA, Bagrov AY. Endogenous marinobufagenin-like factor in acute plasma volume expansion. Clin Exp Hypertens 1998; 20:581-591.
16. 16 Fedorova OV, French AW, Anderson DE. Inhibition of erythrocyte Na-KATPase activity during anticipatory hypoventilation in micropigs. Am J Hypertens 1996; 9:1126-1131.
17. 17 Fedorova OV, Bagrov AY. Inhibition of Na-K ATPase from rat aorta by two Na-K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different α-subunit isoforms. Am J Hypertens 1997; 10:929-935.
18. 18 Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G, Ferrari P. Ouabain-like factor in Milan Hypertensive rats. Am J Physiol 1992; 263:F739-F748.
19. 19 Graves SW, Tao QF, Markides KE, Williams GH, Hollemberg NK. A labile sodium pump inhibitor from the perytoneal dyalisate of hypertensive renal failure patients: estimates of potency. Clin Exp Hypertens 1998; 20:611-616.
20. 20 Schneider R, Wray V, Nimtz M, Lehmann WD, Kirch U, Antolovic R, Schoner W. Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. J Biol Chem 1998; 273:784-792.
21. 21 Schneider R, Antolovic R, Kost H, Sich B, Kirch U, Tepel M, Zidek W, Schoner W. Proscillaridin A immunoreactivity: its purification, transport in blood by a specific binding protein and its correlation with blood pressure. Clin Exp Hypertens 1998; 20:593-600.
22. 22 Kramer HJ, Krampitz G, Bacher A, Krampitz GR, Meyer-Lehnert H. Vanadium diascorbates are strong candidates for endogenous ouabain-like factors in human urine. Biochem Biophys Res Commun 1995; 213:289-294.
23. 23 Kerek F. Macrocyclic compounds made from suboxide units. International patent classification WO 97/25333, 17 July 1997.
24. 24 Hamlyn J, Lu Z, Manunta P, Ludens JH, Kimura K, Shah J, et al. Observation on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clin Exp Hypertens 1998; 20:523-533. By providing data on the biosynthetic pathway and the secretory stimuli, the authors confirmed an endogenous origin of OLF.
25. 25 Shah J, Laredo J, Hamilton BP, Hamlyn J. Effects of angiotensin II on sodium potassium pumps, endogenous ouabain and aldosterone in bovine zona glomerulosa cells. Hypertension 1999; 33:373-377.
26. 26 Shah J, Laredo J, Hamilton BP, Hamlyn J. Different signaling pathways mediate stimulated secretion of endogenous ouabain and aldosterone from bovine adrenocortical cells. Hypertension 1998; 31:463-468.
27. 27 Lichtstein D, Steiniz M, Gati I, Samuelov S, Deutsch J, Orly J. Bufadienolides as endogenous Na-K ATPase inhibitors: biosynthesis in bovine and rat adrenals. Clin Exp Hypertens 1998; 20:573-580.
28. 28 Perrin A, Brasmes B, Chambaz EM, Defaye G. Bovine adrenocortical cells in culture synthesize an ouabain-like compound. Mol Cell Endocrinol 1997; 126:7-15.
29. 29 Doris PA, Haywar-Lester A, Bourne D, Stocco DM. Ouabain production by cultured adrenal cells. Endocrinology 1996, 137:533-539.
30. 30 Leenen FHH, Harmsen E, Yu H. Dietary sodium and central vs peripheral ouabain-like activity in Dahl salt-sensitive rats. Am J Physiol 1994; 267:H1916-H1920.
31. 31 Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, et al. Lett ventricular mass, stroke volume and ouabain-like factor in essential hypertension. Hypertension 1999; 34:450-456. This study reports results on a large-scale quantification of plasma OLF in essential hypertensive patients and parallel measurements of left ventricular mass and cardiac function. OLF is proposed as a new factor that contributes to increased risk of morbid events among essential hypertensive patients.
32. 32 Rossi GP, Manunta P, Hamlyn J, Pavan E, De Toni R, Semplicini A, Pessina AC. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertensive patients. J Hypertens 1995; 13:1181-1191.
33. 33 Graves S, Brown B, Valdes R. An endogenous digoxin-like substance in patients with renal impairment. Ann Intern Med 1983; 99:604-608.
34. 34 Gottlieb SS, Rogowski A, Weinberg M, Krichten CM, Hamilton BP, Hamlyn J. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 1992; 86:420-425.
35. 35 Huang BS, Leenen FHH. Brain ouabain and desensitisation of arterial baroreflex by high sodium in Dahl salt-sensitive rats. Hypertension 1995; 25:372-376.
36. 36 Huang BS, Leenen FHH. Dietary sodium and cardiopulmonary baroreflex control of renal sympathetic nerve activity in SHR. Am J Physiol 1995; 268:H61-H67.
37. 37 Van Huysse JW, Leenen FHH. Role of endogenous brain ouabain in the sympathoexcitatory and pressor effects of sodium. Clin Exp Hypertens 1998; 20:657-668.
38. 38 Boulanger BR, Lilly MP, Hamlyn J, Laredo J, Shurtleff D, Gann DS. Ouabain is secreted by adrenal gland in awake dogs. Am J Physiol 1993; 264:E413-E419.
39. 39 Pamnani MB, Burris JF, Jemionek JF. Humoral sodium potassium pump inhibitory activity in essential hypertension and in normotensive subjects after acute volume expansion. Am J Hypertens 1989; 2:524-531.
40. 40 Alzamov VA, Khirmanov VN, Scherback AI, Krutikov AN, Danilchenko AR, Kireyenkov IS. Atrial and digitalis-like natriuretic hormones in essential hypertension under functional loading. Am J Hypertens 1992; 5:135-139.
41. 41 Goto A, Yamada K, Ishii M, Sugimoto T. Digitalis-like activity in human plasma: relation to blood pressure and sodium balance. Am J Med 1990; 89:420-426.
42. 42 Masugi F, Ogihara T, Hassegawa T, Kumahara Y. Increased plasma ouabain-like factor in essential hypertension with high dietary sodium. J Hypertens 1986; 4 (Suppl 6):S337-S339.
43. 43 Bernini G, Paci A, Sgrò M, Moretti A, Salvetti A. Endogenous digitalis-like factor and ouabain immunoreactivity in adrenalectomized patients and normal subjects after acute and prolonged salt loading. Am J Hypertens 1998; 11:1-7.
44. 44 Bernini G, Sgrò M, Paci A, Ciarimboli G, Salvetti A. Acute saline loading on endogenous digitalis-like factor in normal subjects and in patients with primary aldosteronism. High Blood Pressure 1996; 5:6-12.
45. 45 Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Conti F, et al. PST 2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol ExpTher 1998, 285:89-94. This study offers a new insight into the molecular mechanism modifications induced by ouabain/OLF and a new approach to hypertension therapy.
46. 46 Ferrari P, Ferrandi M, Torielli L, Tripodi G, Melloni P, Bianchi G. PST 2238: a new antihypertensive compound that modulates Na-K ATPase and antagonizes the pressor effect of OLF. Cardiovasc Drug Rev 1999; 17:39-57.
47. 47 Manunta P, Rivera R, Ferrandi M, D'Amico M, Buzzi L, Lanzani C, et al. Increased plasma ouabain-like factor during acute salt depletion in hypertensive patients. J Hypertens 1998; 16 (Suppl 2):P1746.
48. 48 Li M, Wong KS, Martin A, Whitworth A. Adrenocorticotrophin-induced hypertension in rats. Am J Hypertens 1994; 7:59-68.
49. 49 De Angelis C, Farrace S, Urbani L, Porcu S, Ferrari C, D'Amlio R, et al. Effects of high altitude exposure on plasma and urinary digoxin-like immunoreactivity substance. Am J Hypertens 1992; 5:600-607.
50. 50 Komiyama Y, Mori T, Okuda K, Munakata M, Murakami T, Masuda M, et al. Effects of intracerebroventricular administration of 6-hydroxydopamine on ouabain-like immunoreactivity in plasma and the hypothalamo-pituitary axis in rats. J Hypertens 1996; 14:447-452.
51. 51 Garay RP, Alvarez-Guerra M, Alda JO, Nazaret C, Soler A, Vargas F. Regulation of renal Na-K-Cl cotransporter NKCC2 by humoral natriuretic factors: relevance in hypertension. Clin Exp Hypertens 1998; 20:675-682.
52. 52 Foulkes R, Ferrario RG, Salvati P, Bianchi G. Differences in ouabain-induced natriuresis between isolated kidneys of Milan hypertensive and normotensive rats. Clin Sci 1992; 82:185-190.
53. 53 Yates NA, McDougall JC. Effects of direct renal arterial infusion of bufalin and ouabain in conscious sheep. Br J Pharmacol 1993; 108:627-630.
54. 54 Yates NA, McDougall JC. Effect of volume expansion on the natriuretic response to ouabain infusion. Renal Physiol Biochem 1995; 18:311-320.
55. 55 Huang Bing S, Shetrni J Verasingham, Leenen FHH. Brain ouabain, ang II, and sympathoexcitation by chronic central sodium loading in rats. Am J Physiol 1998; 274:H1269-H1276.
56. 56 Yamada K, Goto A, Nagoshi H, Hui C, Omata M. Role of brain ouabain-like compound in central nervous system-mediated natriuresis in rats. Hypertension 1994; 23:1027-1031.
57. 57 Bianchi G, Ferrari P, Barber B. Lessons from experimental genetic hypertension. In: Hypertension: pathophysiology, diagnosis and management. Laragh JH, Brenner BM (editors). New York: Raven Press Ltd; 1995. pp. 1261-1280.
58. 58 Bianchi G, Tripodi G, Casari G, Salardi S, Barber B, Torielli L, et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci U S A 1994; 91:3999-4003.
59. 59 Ferrandi M, Tripodi G, Salardi S, Florio F, Modica R, Barassi P, et al. Renal Na-K ATPase in genetic hypertension. Hypertension 1996; 28:1018-1025.
60. 60 Ferrari P, Ferrandi M, Tripodi G, Torielli L, Padoani G, Minotti E, et al. PST 2238: a new antihypertensive compound that modulates Na-KATPase in genetic hypertension. J Pharmacol Exp Ther 1999, 288:1074-1083.
61. 61 Ferrandi M, Salardi S, Tripodi G, Barassi P, Goldshlager R, Manunta P, et al. Evidence for an interaction between adducin and Na-K ATPase: relation to genetic hypertension. Am J Physiol 1999; 277:H1338-H1349.
62. 62 Rayson BM. Rates of synthesis and degradation of Na-K ATPase during chronic ouabain treatment. Am J Physiol 1989; 256:C75-C80.
63. 63 Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphism of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349:1353-1357.
64. 64 Manunta P, Cusi D, Barlassina C, Righetti M, Lanzani C, D'Amico M, et al. Adducin polymorphism and renal sodium handling in essential hypertensive patients. Kidney Int 1998; 53:1471-1478.
65. 65 Manunta P, Burnier M, D'Amico M, Buzzi L, Maillard M, Barlassina C, et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 1999; 33:694-697.
66. 66 Kometiani P, Li J, Gnudi L, Kahn BB, Askari A, Xie Z. Multiple signal transduction pathways link Na-K ATPase to growth-related genes in cardiac myocytes: the role of Ras and mitogen activated protein kinase. J Biol Chem 1998; 273:15249-15256.
67. 67 Huang L, Li H, Xie Z. Ouabain-induced hypertrophy in cultured cardiac myocytes is accompanied by changes in expression in several late response genes. J Mol Cell Cardiol 1997; 29:429-437.
68. 68 Nguyen AT, Hayward Lester A, Sabatini S, Doris PA. Renal Na-KATPase in SHR: studies of activity and gene expression. Clin Exp Hypertens 1998; 20:641-646.
69. 69 Tripodi G, Szpirer C, Reina C, Szpirer J, Bianchi G. Polymorphism of alpha-adducin gene in genetic hypertension and mapping of the gene to rat chromosome 1q55. Biochem Biophys Res Commun 1997; 237:685-689.
70. 70 Doris PA. Ouabain in plasma from spontaneous hypertensive rats. Am J Physiol 1994; 266:H360-H364.